Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have been given an average rating of “Moderate Buy” by the fourteen analysts that are currently covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $52.56.

A number of analysts have commented on the stock. HC Wainwright cut their price objective on shares of Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating for the company in a report on Friday, December 13th. Guggenheim restated a “neutral” rating on shares of Keros Therapeutics in a research report on Friday, January 17th. Truist Financial reduced their price objective on Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating on the stock in a research report on Monday, December 23rd. William Blair cut Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. Finally, Scotiabank cut their target price on Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating for the company in a research note on Thursday, January 16th.

Keros Therapeutics Stock Down 0.8 %

Shares of NASDAQ KROS opened at $10.20 on Thursday. The firm has a 50-day simple moving average of $20.35 and a 200-day simple moving average of $42.86. The stock has a market capitalization of $413.20 million, a price-to-earnings ratio of -1.96 and a beta of 1.39. Keros Therapeutics has a 52 week low of $9.77 and a 52 week high of $73.00.

Institutional Trading of Keros Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. AlphaQuest LLC boosted its stake in Keros Therapeutics by 469.0% during the fourth quarter. AlphaQuest LLC now owns 3,596 shares of the company’s stock worth $57,000 after buying an additional 2,964 shares during the period. KBC Group NV lifted its holdings in shares of Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after acquiring an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after purchasing an additional 280 shares during the period. Values First Advisors Inc. acquired a new stake in Keros Therapeutics in the 3rd quarter valued at approximately $89,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in Keros Therapeutics in the 4th quarter valued at approximately $90,000. 71.56% of the stock is owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.